November 24, 2020

Clearsight Advises RRD International in its Acquisition by Uniphar

Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce another successful Life Sciences transaction.  Clearsight served as the exclusive strategic financial advisor to RRD International, LLC (“RRD” or “The Company”) in its acquisition by Uniphar Plc (“Uniphar”). This deal marks Clearsight’s sixth Healthcare/Life Sciences transaction since last summer.

RRD is a US-based pharmaceutical advisory group providing outsourced strategic consulting and execution services throughout the early stages of product development. RRD’s comprehensive approach integrates all critical development disciplines including strategy, regulatory, clinical, and CMC across a broad range of product classes and therapeutic areas and has supported the FDA regulatory approval of over 100 assets. The Company’s acquisition by Uniphar will facilitate the growing demand for Uniphar’s delivery of US-based expanded-access programs. RRD’s rich history of providing expert-level product development support to biopharmaceutical companies across the globe will form an integral part of Uniphar’s US offering moving forward.

Scott Tarrant, CEO of RRD, lauded the deal, saying, “At RRD, we are committed to being trusted partners to our clients as they transform early-stage product candidates into new medicines. Likewise, when we were looking for a financial advisor, we heavily emphasized the importance of expertise, industry knowledge, creativity and collaboration. We found all of those values in Clearsight. The team worked diligently to ensure that Uniphar was the right partner and then negotiated on our behalf to present a holistic narrative of our company. Finding an advisor that shares our company values was instrumental to completing this transaction.”

Joel Kallett, Co-founder and Managing Director of Clearsight, remarked, “Clearsight is thrilled to have supported RRD in the transaction with Uniphar. The RRD team has created a world-class pharmaceutical R&D advisory business that will undoubtedly provide Uniphar with the people and capabilities needed to expand their array of services as well as move more deliberately into the US-market. We are confident their combined entity will create a win-win for all stakeholders.”